Clinical value of miR-101-3p combined with PSPC1 detection in breast cancer disease and prognosis assessment

Abstract:Objective To study the clinical value of miR-101-3p combined with PSPC1 detection in breast cancer condition and prognosis evaluation. Methods The research subjects were 107 breast cancer patients(BRC group) and 71 patients with benign breast diseases(CON group) treated in the Department of Thyroid and Breast Surgery of Honghu People's Hospital from January 2019 to January 2022. Real-time fluorescence quantitative polymerase chain reaction was used to detect the expression of miR-101-3p and PSPC1; Pearson correlation was used for correlation analysis; receiver operating characteristic(ROC) curve was used to analyze the sensitivity and specificity of miR-101-3p combined with PSPC1 in predicting poor prognosis of breast cancer; multivariate Logistic regression was used to analyze the risk factors for poor prognosis of breast cancer; Kaplan-Meier curve was used to analyze the relationship between miR-101-3p, PSPC1 expression and survival of breast cancer. Results The expression of miR-101-3p and PSPC1 in cancer tissues of BRC group was lower/higher than that in adjacent tissues of BRC group and CON group(F/P=158.778/<0.001, 467.306/<0.001). The expression of miR-101-3p was low in patients with positive circulating tumor cells, pathological grade 3, primary lesion T stage T3-T4, lymph node N stage N2-N3, distant metastasis M stage M1 and stage Ⅲ-Ⅳ. In patients with negative circulating tumor cells, pathological grade 1-2, primary lesion T stage T1-T2, lymph node N stage N0-N1, distant metastasis M stage M0 and stage Ⅰ-Ⅱ(t/P=7.067/<0.001, 5.975/<0.001, 7.502/<0.001, 5.897/<0.001, 4.546/<0.001, 6.277/<0.001), PSPC1 The expression was higher than that in patients with negative circulating tumor cells, pathological grade 1-2, primary lesion T stage T1-T2, lymph node N stage N0-N1, distant metastasis M stage M0 and stage Ⅰ-Ⅱ(t/P=5.178/<0.001, 5.687/<0.001, 6.114/<0.001, 4.505/<0.001, 3.655/<0.001, 5.156/<0.001); br="" the="" expression="" of="" mir-101-3p="" in="" group="" c="" was="" negatively="" correlated="" with="" circulating="" tumor="" pathological="" primary="" lesion="" t="" lymph="" node="" n="" distant="" metastasis="" m="" and="" tnm="" p="7.174/0.001," pspc1="" their="" combination="" were="" positively="" stage="" 0.041="" .="" aucs="" for="" poor="" prognosis="" patients="" adenocarcinoma="" respectively.="" combined="" prediction="" superior="" to="" that="" each="" positive="" grade="" 0.89="" independent="" risk="" factors="" breast="" cancer="" median="" survival="" time="" 0.73="" significantly="" lower="" than="">0.73 or PSPC1<0.89(Log rank χ²=11.952, P<0.001). Conclusion The expression of miR-101-3p and PSPC1 in breast cancer is directly related to the disease, prognosis and survival, and has a certain clinical value in the evaluation of breast cancer disease and prognosis. The combination of the two can synergistically improve the clinical value in breast cancer.